Anti-CD30 (BER-H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice

British Journal of Haematology

Volumn 92, Issue 4, 1996, Pages 872-879

  Terenzi, Adelmo ^a   Bolognesi, Andrea ^b   Pasqualucci, Laura ^a   Flenghi, Leonardo ^a   Pileri, Stefano ^b   Stein, Harald ^c   Marshall, Kadin ^d   Bigerna, Barbara ^a   Polito, Letizia ^b   Tazzari, Pier Luigi ^b   Martelli, Massimo F ^a   Stirpe, Fiorenzo ^b   Falini, Brunangelo ^a,e  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e Istituto di Ematologia   (Italy)

Author keywords

CD30 antigen; Hodgkin's disease; Immunotoxins; Monoclonal antibodies; Ribosome inactivating proteins

Indexed keywords

CD30 ANTIBODY; CD30 ANTIGEN; IMMUNOTOXIN; MOMORDIN; POKEWEED ANTIVIRUS PROTEIN; SAPORIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG TOXICITY; HODGKIN DISEASE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SCID MOUSE; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD30; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HODGKIN DISEASE; HUMANS; IMMUNOTOXINS; MICE; MICE, SCID; N-GLYCOSYL HYDROLASES; PLANT PROTEINS; RIBOSOMAL PROTEINS; TUMOR CELLS, CULTURED;

EID: 0029880032     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1995.404942.x     Document Type: Article

References (44)

1. Amlot, P.L., Stone, M.J., Cunningham, D., Fay, J., Newman, J., Collins, R., May, R., McCarthy, M., Richardson, J., Ghetie, V., Ramilo, O., Thorpe, P.E., Uhr, J.W. & Vitetta, E.S. (1993) A phase I study of an anti-CD22-deglycosylated ricin A-chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood. 82, 2624-2633.
2. Barbieri, L., Battelli, M.G. & Stirpe, F. (1990) Blood clearance and organ distribution and tissue concentration of native, homopolymerized and IgG-conjugated ribosome-inactivating proteins. Xenobiotica, 20, 1351-1341.
3. Barbieri, L., Battelli, M.G. & Stirpe, F. (1993) Ribosome-inactivating proteins from plants. Biochimica et Biophysica Acta, 1154, 237-282.
4. Barbieri, L., Dinota, A., Gobbi, M., Tazzari, P.L., Rizzi, S., Bontadini, A., Lemoli, R.M., Tura, S. & Stirpe, F. (1989) Immunotoxins containing saporin 6 and monoclonal antibodies recognizing plasma cell-associated antigens: effects on target cells and on normal myeloid precursors (CFU-GM). European Journal of Haematology, 43, 238-245.
5. Barbieri, L., Stoppa, C. & Bolognesi, A. (1987) Large-scale chromatographic purification of ribosome-inactivating proteins. Journal of Chromatography, 408, 235-243.
6. Battelli, M.G., Barbieri, L. & Stirpe, F. (1990) Toxicity of and histological lesions caused by ribosome-inactivating proteins, their IgG-conjugates, and their homopolymers. Acta Pathologica Microbiologica et Immunologica Scandinavica, 98, 585-593.
7. Battelli, M.G., Buonamici, L., Bolognesi, A. & Stirpe, F. (1994) In vivo and in vitro uptake of an anti-CD30/saporin immunotoxin by rat liver parenchymal and non-parenchymal cells. Hepatology (in press).
8. Blakey, D.C., Skilleter, D.N., Price, R.J. & Thorpe, P.E. (1988) Uptake of native and deglycosylated ricin A-chain immunotoxins by mouse liver parenchymal and non-parenchymal cells in vitro and in vivo. Biochimica et Biophysica Acta, 968, 172-178.
9. Bolognesi, A., Tazzari, P.L., Tassi, C., Gromo, G., Gobbi, M. & Stirpe, F. (1992) comparison of anti-lymphocyte immunotoxins containing different ribosome-inactivating protein and antibodies. Clinical andExperimental Immunology, 89, 341-346.
10. Cordell, J.L., Falini, B., Erber, W.N., Ghosh, A.K., Abdulaziz, Z., MacDonald, S., Pulford, K.A.F., Stein, H. & Mason, D.Y. (1984) Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). Journal of Histochemistry and Cytochemistry, 32, 219-229.
11. Diehl, V., Pfreundschuh, M., Fonatsch, C., Stein, H., Falk, M., Burrichter, H. & Schaadt, M. (1985) Phenotypic and genotypic analysis of Hodgkin's disease derived cell lines: histopathological and clinical implications. Cancer Surveys, 4, 393-419.
12. Durkop, H., Latza, U., Hummel, M., Eitelbach, F., Seed, B. & Stein, H. (1992) Molecular cloning and expression of a new member of the Nerve Growth Factor Receptor family which is characteristic for Hodgkin's disease. Cell, 68, 421-428.
13. Ellman, G.I., (1959) Tissue sulphydryl groups. Archives of Biochemistry and Biophysics, 82, 70-78.
14. Ey, E.L., Prowse, S.J. & Jenkin, C.R. (1978) Isolation of pure IgG1. IgG2a and IgG2b immunoglobulin from mouse serum using protein A-Sepharose. Immunochemistry, 15, 429-437.
15. Falini, A., Bolognesi, A., Flenghi, L., Tazzari, P.L., Broe, M.K., Stein, H., Durkop, H., Aversa, F., Corneli, P., Pizzolo, G., Barbabietola, G., Sabattini, E., Pileri, S., Martelli, M.F. & Stirpe, F. (1992a) Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet, 339, 1195-1196.
16. Falini, B., Flenghi, L., Fedeli, L., Broe, M.K., Stein, H.E., Dürkop, H., Bigerna, B., Barbabietola, G., Venturi, S., Aversa, F., Pizzolo, G., Bartoli, A., Pileri, S., Sabattini, E., Palumbo, R. & Martelli, M.F. (1992b) In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence. British Journal of Haematology, 82, 38-45.
17. Falini, B., Pasqualucci, L., Flenghi, L., Terenzi, A., Bolognesi, A., Tazzari, P.L., Stein, H., Pizzolo, G., Martelli, M.F. & Stirpe, F. (1993) Therapy of refractory Hodgkin's disease with monoclonal anti-CD30/saporin immunotoxin. Fifth International Conference on Malignant Lymphoma, Lugano, June 1993, abstract book, p. 66.
18. Falini, B., Pileri, S., Pizzolo, G., Dürkop, H., Flenghi, L., Stirpe, F., Martelli, M.F. & Stein, H. (1995) CD30 (Ki-1) molecule: a new cytokine receptor of the Tumour Necrosis Factor Receptor superfamily as a tool for diagnosis and immunotherapy. Blood, 85, 1-14.
19. Frankel, A.E. (1988) Immunotoxins. Kluwer Academic Press, Boston.
20. Grossbard, M.L., Freedman, A.S., Ritz, J., Coral, F., Goldmacher, V.S., Eliseo, L., Spector, N., Dear, K., Lambert, J.A., Blatter, W.A., Taylor, J.A. & Nadler, L.M. (1992a) Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood, 79, 576-585.
21. Grossbard, M.L., Press, O.W., Applebaum, F.R., Bernstein, I.D. & Nadler, LM. (1992b) Monoclonal antibody-based therapies of leukemia and lymphoma. Blood, 80, 863-878.
22. Harkonen, S., Stoudemire, J., Mishak, R., Spitler, L.E., Lopez, H. & Scannon, P. (1987) Toxicity and immunogenicity of monoclonal antimelanoma antibody-ricin A-chain immunotoxin in rats. Cancer Research, 47, 1377-1382.
23. Harris, N.L., Jaffe, E.S., Stein, H., Banks, P.M., Chan, J.K.C., Cleary, M.L., Delsol, G., De Wolf Peeters, C., Falini, B., Gatter, K.C., Grogan, T.M., Isaacson, P., Knowles, D.M., Mason, D.Y., Muller-Hermelink, H.K., Pileri, S.A., Piris, M.A., Ralfkier, E. & Warnke, R.A. (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International lymphoma Study Group. Blood, 84, 1361-1392.
24. + anaplastic large cell lymphoma: a distinct clinicopathologic entity. Annals of Oncology, 5, 25-30.
25. + anaplastic large cell lymphoma: establishment and characterization of a new tumor cell line transplantable to SCID mice. Blood, 76, 354.
26. Krakauer, T. (1991) Immunoenhancing effects of ricin. Immunopharmacology and Immunotoxicology, 13, 357-366.
27. LeMaistre, C.F., Rosen, S., Frankel, A., Kornfeld, S., Saria, E., Meneghetti, C., Drajesk, J., Fushwild, D., Scannon, P. & Byers, V. (1991) Phase-1 trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. Blood, 78, 1173-1182.
28. Licastro, F., Morini, M.C., Bolognesi, A. & Stirpe, F. (1993) Ricin induces the production of tumour necrosis factor-α and interleukin-1 by human peripheral blood mononuclear cells. Biochemical Journal, 294, 517-520.
29. Pai, L.H. & Pastan, I. (1993) Immunotoxin therapy of cancer. Journal of the American Medical Association, 269, 78-81.
30. Pasqualucci, L., Wasik, M., Teicher, B.A., Flenghi, L., Bolognesi, A., Stirpe, F., Falini, B. & Kadin, M.E. (1995) Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in SCID mice xenografted with human CD30 anaplastic large cell lymphoma. Blood, 85, 2139-2146.
31. Schwarting, R., Gerdes, J., Dürkop, H., Falini, B., Pileri, S. & Stein, H. (1989) Ber-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood, 74, 1678-1689.
32. Skilleter, D.N., Paine, A.J. & Stirpe, F. (1981) A comparison of the accumulation of ricin by hepatic parenchymal and non-parenchymal cells and its inhibition of protein synthesis. Biochimica et Biophysica Acta, 677, 495-500.
33. Smith, C.A., Gruss, H.J., Davis, T., Anderson, D., Farrah, T., Baker, E., Sutherland, G.R., Brannan, C.I., Copeland, N.G., Jenkins, N.A., Grabstein, K.H., Gliniak, B., Macalister, I.B., Fanslow, W., Alderson, M., Falk, B., Gimpel, S., Fillis, S., Din, W.S., Goodwin, R.G. & Armitage, R.J. (1994) CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytochines with homology to TNF, Cell, 73, 1349-1360.
34. Stansfeld, A.G., Diebold, J., Kapanci, Y., Kelenyi, G., Lennert, K., Mioduszewska, O., Noel, H., Rilke, F., Sundstrom, C., Van Unnik, J.A.M. & Wright, D.H. (1988) Updated Kiel classification for lymphomas. Lancet, i, 292-293.
35. Stein, H., Gerdes, J. & Falini, B. (1987) Phenotypic and genotypic markers in malignant lymphomas: cellular origin of Hodgkin and Sternberg-Reed cells and implications for the classification of T-cell and B-cell lymphomas. Pathology of Cell Receptors and Tumor Markers (ed. by G. Sefert and K. Hübner), pp. 121-144. Gustav Fisher Verlag, Stuttgart.
36. Stein, J., Mason, D.Y., Gerdes, J., O'Connor, N., Wainscoat, J., Pallesen, G., Gatter, K.C., Falini, B., Delsol, G., Lemke, H., Schwarting, R. & Lennert, K. (1985) The expression of the Hodgkin's disease-associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood, 66, 848-858.
37. Stirpe, F., Barbieri, L., Battelli, M.G., Soria, M. & Lappi, D.A. (1992) Ribosome-inactivating proteins from plants: present status and future prospects. Biotechnology, 10, 405-412.
38. Strocchi, P., Barbieri, L. & Stirpe, F. (1992) Immunological properties of ribosome-inactivating proteins and of a saporin-IgG conjugate. Journal of Immunological Methods, 155, 57-63.
39. + lymphoma: in vitro evaluation. British Journal of Haematology, 81, 203-211.
40. Uckun, F.M., Manivel, C., Arthur, D., Chelstrom, L.M., Finnegan, D., Tuel-Ahlgren, L., Irvin, J.D., Myers, D.E. & Gunther, R. (1992) In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood, 79, 2201-2214.
41. Uhr, J.W. & Vitetta, E.S. (1993) Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome. Experimental Cell Research, 206, 227-234.
42. Vallera, D.A. (1994) Immunotoxins: will their clinical promise be fullfilled? Blood, 83, 309-317.
43. Vitetta, E.S., Stone, M., Amlot, P., Fay, J., May, R., Till, M., Newman, J., Clark, P., Collins, R., Cunningham, V., Ghetie, V., Uhr, J.W. & Thorpe, P.E. (1991) Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Research, 51, 4052-4058.
44. Vitetta, E.S., Thorpe, P.E. & Uhr, J.W. (1993) Immunotoxins: magic bullets or misguided missiles? Immunology Today, 14, 252-259.